

- [0157] 22. Trobridge, G D, and Russell, D W (1998). Helper-free foamy virus vectors. *Human gene therapy* 9: 2517-2525.
- [0158] 23. Trobridge, G, Josephson, N, Vassilopoulos, G, Mac, J, and Russell, D W (2002). Improved foamy virus vectors with minimal viral sequences. *Molecular therapy: the journal of the American Society of Gene Therapy* 6: 321-328.
- [0159] 24. Trobridge, G, and Russell, D W (2004). Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. *J Virol* 78: 2327-2335.
- [0160] 25. Bauer, T R, Jr., Allen, J M, Hai, M, Tuschong, L M, Khan, I F, Olson, E M, et al. (2008). Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. *Nat Med* 14: 93-97.
- [0161] 26. Trobridge, G D, Miller, D G, Jacobs, M A, Allen, J M, Kiem, H P, Kaul, R, et al. (2006). Foamy virus vector integration sites in normal human cells. *Proc Natl Acad Sci USA* 103: 1498-1503.
- [0162] 27. Nasimuzzaman, M, Kim, Y S, Wang, Y D, and Persons, D A (2014). High-titer foamy virus vector transduction and integration sites of human CD34(+) cell-derived SCID-repopulating cells. *Molecular therapy Methods & clinical development* 1: 14020.
- [0163] 28. Bauer, T R, Jr., Tuschong, L M, Calvo, K R, Shive, H R, Burkholder, T H, Karlsson, E K, et al. (2013). Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency. *Molecular therapy: the journal of the American Society of Gene Therapy* 21: 964-972.
- [0164] 29. Uchiyama, T, Adriani, M, Jagadeesh, G J, Paine, A, and Candotti, F (2012). Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome. *Molecular therapy: the journal of the American Society of Gene Therapy* 20: 1270-1279.
- [0165] 30. Chatziandreou, I, Siapati, E K, and Vassilopoulos, G (2011). Genetic correction of X-linked chronic granulomatous disease with novel foamy virus vectors. *Exp Hematol* 39: 643-652.
- [0166] 31. Si, Y, Pulliam, A C, Linka, Y, Ciccone, S, Leurs, C, Yuan, J, et al. (2008). Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells. *Blood* 112: 4458-4465.
- [0167] 32. Anderson, D C, and Springer, T A (1987). Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. *Annu Rev Med* 38: 175-194.
- [0168] 33. Trowald-Wigh, G, Hakansson, L, Johannisson, A, Norrgren, L, and Hard of Segerstad, C (1992). Leucocyte adhesion protein deficiency in Irish setter dogs. *Vet Immunol Immunopathol* 32: 261-280.
- [0169] 34. Kijas, J M, Bauer, T R, Jr., Gafvert, S, Marklund, S, Trowald-Wigh, G, Johannisson, A, et al. (1999). A missense mutation in the beta-2 integrin gene (ITGB2) causes canine leukocyte adhesion deficiency. *Genomics* 61: 101-107.
- [0170] 35. Nasimuzzaman, M, and Persons, D A (2012). Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. *Molecular therapy: the journal of the American Society of Gene Therapy* 20: 1158-1166.
- [0171] 36. Plochmann, K, Horn, A, Gschmack, E, Armbruster, N, Krieg, J, Wiktorowicz, T, et al. (2012). Heparan sulfate is an attachment factor for foamy virus entry. *J Virol* 86: 10028-10035.
- [0172] 37. Burova, E, and Ioffe, E (2005). Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. *Gene Ther* 12 Suppl 1: S5-17.
- [0173] 38. Allay, J A, Sleep, S, Long, S, Tillman, D M, Clark, R, Carney, G, et al. (2011). Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. *Human gene therapy* 22: 595-604.
- [0174] 39. Tiscornia, G, Singer, O, and Verma, I M (2006). Production and purification of lentiviral vectors. *Nature protocols* 1: 241-245.
- [0175] 40. Hanawa, H, Kelly, P F, Nathwani, A C, Persons, D A, Vandergriff, J A, Hargrove, P, et al. (2002). Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. *Molecular therapy: the journal of the American Society of Gene Therapy* 5: 242-251.
- [0176] 41. Sastry, L, Xu, Y, Cooper, R, Pollok, K, and Cornetta, K (2004). Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. *Human gene therapy* 15: 221-226.
- [0177] 42. Rowley, S D, and Anderson, G L (1993). Effect of DMSO exposure without cryopreservation on hematopoietic progenitor cells. *Bone Marrow Transplant* 11: 389-393.
- [0178] 43. Han, D L, Liu, K Q, Guo, S S, Zhu, H L, Huang, C, and Wang, B H (2008). [Dose-effect relationship of DMSO and Tween 80 influencing the growth and viability of murine bone marrow-derived cells in vitro]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 16: 377-380.
- [0179] 44. Pal, R, Mamidi, M K, Das, A K, and Bhonde, R (2012). Diverse effects of dimethyl sulfoxide (DMSO) on the differentiation potential of human embryonic stem cells. *Arch Toxicol* 86: 651-661.
- [0180] 45. Akinc, A, Thomas, M, Klibanov, A M, and Langer, R (2005). Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. *The journal of gene medicine* 7: 657-663.
- [0181] 46. Boussif, O, Lezoualc'h, F, Zanta, M A, Mergny, M D, Scherman, D, Demeneix, B, et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. *Proc Natl Acad Sci USA* 92: 7297-7301.
- [0182] 47. Zufferey, R (2002). Production of lentiviral vectors. *Current topics in microbiology and immunology* 261: 107-121.
- [0183] 48. Eaves, G N, and Jeffries, C D (1963). Isolation and Properties of an Exocellular Nuclease of *Serratia Marcescens*. *Journal of bacteriology* 85: 273-278.
- [0184] 49. Bess, J W, Jr., Gorelick, R J, Bosche, W J, Henderson, L E, and Arthur, L O (1997). Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. *Virology* 230: 134-144.
- [0185] 50. Segura, M M, Kamen, A, Trudel, P, and Gamier, A (2005). A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. *Biotechnol Bioeng* 90: 391-404.